Rockville Centre, NY (PRWEB) May 05, 2012
Researchers at The Long Island Brain Tumor Center at Neurological Surgery, P.C. (NSPC) are contrast a personalized cancer vaccine well known as DCVax-Brain a unique treatment done from patients own cells with patients newly diagnosed with glioblastoma, an assertive brain cancer. The Phase II investigate is now enrolling participants, and is being conducted at Neurological Surgery, P.C. offices in Nassau and Suffolk Counties, New York. The Long Island Brain Tumor Center at NSPC is the usually investigate site on Long Island.
Because glioblastoma is the many assertive sort of brain cancer, we wish to make sure our patients have the ultimate accessible treatments, as well as access to a large portfolio of initial therapies, says neuro-oncologist Jai Grewal, M.D., principal questioner on the investigate and co-director of The Long Island Brain Tumor Center. We motionless to offer this clinical hearing since rough data from progressing studies showed DCVax softened survival.
Co-investigators on the investigate embody neuro-oncologist J. Paul Duic, M.D., co-director of The Long Island Brain Tumor Center, and neurosurgeons Jeffrey A. Brown, M.D., F.A.C.S., F.A.A.N.S., Lee Tessler, M.D., F.A.C.S., F.A.A.N.S., and Ramin Rak, M.D. A number of Long Island hospitals are collaborating with the Center on this study.
DCVax




